Vascular endothelial growth factor (VEGF) antibodies act on the Enhancer RNAs (eRNAs) to enhance their growth factor binding abilities and increase their size and number. Vascular endothelial growth factor commonly referred to as vascular permeability protein is an indicator protein produced in vascular smooth muscle cells, which stimulates the proliferation of vascular tissue. To be more precise, VEGF antibodies consists of two subfamilies of vascular growth factors, the vascular-derived growth factor (VDG), and the platelet-derived growth factors (PDG). The primary function of VEGF antibodies in the body is to regulate vascular permeability, but it has also been found to stimulate cell growth and survival in many organs. Thus, it is useful in organ maintenance and repair. In addition, vascular endothelial growth factor (VEGF) antibodies has been shown to enhance wound healing in animal models and in vitro tests.
Market Dynamics
The main factor influencing the growth of the vascular endothelial growth factor (VEGF) antibodies is the increasing prevalence of diseases such as macular degeneration and cancer. For instance, according to the U.S. Cancer Organization, in 2020, numbers of new cancer cases were approximately 1.8 million among them death cases were approximately 606,520. The inclination towards targeted therapies is increasing owing to the lesser side effects of targeted therapies when compared with traditional therapies such as chemotherapy. Therapies present in the market have displayed better clinical results in cancer as well as in age-related macular degeneration (AMD). These have attracted the interest of manufacturers and investors towards the vascular endothelial growth factor (VEGF) antibodies market.
However, the high costs of these medicines, subsequent launches, and biosimilar research are the main restraining factors hindering the growth of the vascular endothelial growth factor (VEGF) antibodies market.
This market is distributed in five regions that include North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America. Among these North America is estimated to hold a significant share of the vascular endothelial growth factor (VEGF) antibodies market owing to the presence of key manufacturers in the region and the rapid expansion of cancer organizations. For instance, according to the American Cancer Society, as of 2019, there were 7 Basic Laboratory Cancer Centers, 13 Cancer Centers, and 51 Comprehensive Cancer Centers. In all counting the NCI designated places there are almost 1500 cancer centers in the U.S. In the Asia Pacific, the vascular endothelial growth factor (VEGF) antibodies market is estimated to witness significant growth owing to sophisticated insurance facilities and favorable governmental policies.
Competitive Analysis
Key players operating in the vascular endothelial growth factor (VEGF) antibodies market include ThromboGenics Inc, Ceres Oncology Pty Ltd, Valeant Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Bayer Pharma AG, Eli Lilly and Company, Novartis, Exelixis Inc., and Genentech Inc.
In May 2018, U.S. FDA gave priority review status to Tecentriq that is manufactured by Roche for treating patients suffering from non-small and non-squamous lung cancer. Likewise in January 2018, European Commission granted approval for Bevacizumab manufactured by Avastin, for treating patients suffering from ovarian, cervical, kidney, glioblastoma, lung, and colorectal cancer.
No comments:
Post a Comment